Eugene R. Hickey - Concepedia

Author

Eugene R. Hickey

Boehringer Ingelheim (United States)ORCID

Also Known As

E Hickey, E. HICKEY, E. Hickey, E. R. HICKEY, E. R. Hickey, E.R. Hickey, Erin Hickey, Eugene Hickey, Eugene R. Hickey, Hickey, Eugene

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (United States)Boehringer Ingelheim (Germany)Boehringer Ingelheim (France)Boehringer Ingelheim (Japan)The Ohio State University

About

Eugene R. Hickey is an author at Boehringer Ingelheim (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	20	2.6K
2	Natural Sciences	13	17	1.8K
3	Biochemistry	13	17	1.7K
4	Engineering	10	11	390
5	Applied Physics	3	3	139

Eugene R. Hickey

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase Stefan Kubicek, Roderick J. O’Sullivan, Elias August, Molecular Cell Histone ModificationsChromatinChromatin RemodelingMedicineNatural Sciences	2007	841
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Christopher Pargellis, Liang Tong, Laurie Churchill, Nature Structural Biology Molecular PharmacologyDrug TargetMolecular PhysiologySignal TransductionBiochemistry	2002	832
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate John R. Regan, Steffen Breitfelder, Pier F. Cirillo, Journal of Medicinal Chemistry Drug TargetP38 Map KinaseAtp Binding SitePharmacotherapyChemical Biology	2002	349
Structural Basis of Constitutive Activity and a Unique Nucleotide Binding Mode of Human Pim-1 Kinase Kevin Qian, Lian Wang, Eugene R. Hickey, Journal of Biological Chemistry	2004	285
The kinetics of binding to p38 MAP kinase by analogues of BIRB 796 John R. Regan, Christopher A. Pargellis, Pier F. Cirillo, Bioorganic & Medicinal Chemistry Letters	2003	111
Structure−Activity Relationships of the p38α MAP Kinase Inhibitor 1-(5-<i>tert</i>-Butyl-2-<i>p</i>-tolyl-2<i>H</i>-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796) John R. Regan, Alison J. Capolino, Pier F. Cirillo, Journal of Medicinal Chemistry Drug TargetBirb 796Chemical BiologyPharmaceutical ChemistryMolecular Pharmacology	2003	105
Stabilization of a new superconducting phase by low temperature fluorination of La2CuO4 Bernard Chevalier, A. Tressaud, Bruno Lépine, Physica C Superconductivity Critical CurrentsMaterials ScienceSuperconducting MaterialHigh-tc SuperconductivityEngineering	1990	82
A GPBAR1 (TGR5) Small Molecule Agonist Shows Specific Inhibitory Effects on Myeloid Cell Activation In Vitro and Reduces Experimental Autoimmune Encephalitis (EAE) In Vivo Nuruddeen D. Lewis, Lori Patnaude, Josephine Pelletier, PLoS ONE Gpbar1 AgonistImmunologyImmune DysregulationProprietary Gpbar1 AgonistInflammation	2014	73
An in Silico Method for Predicting Ames Activities of Primary Aromatic Amines by Calculating the Stabilities of Nitrenium Ions Jörg Bentzien, Eugene R. Hickey, Raymond A. Kemper, Journal of Chemical Information and Modeling EngineeringNitrenium HypothesisChemical AnalysisMolecular BiologyOrganic Chemistry	2010	70
Hit to Lead Account of the Discovery of a New Class of Inhibitors of Pim Kinases and Crystallographic Studies Revealing an Unusual Kinase Binding Mode Kevin Qian, Lian Wang, Charles L. Cywin, Journal of Medicinal Chemistry Pim KinasesPim-2 SarMolecular BiologyLead IdentificationChemical Biology	2009	69

Page 1